Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.

J Gynecol Oncol. 2014 Jul;25(3):221-8. doi: 10.3802/jgo.2014.25.3.221. Epub 2014 Jul 3.

PMID:
25045435
[PubMed - in process]
Free PMC Article
2.

GCIG (Gynecological Cancer Inter Group) Consensus Review for Endometrial Stromal Sarcoma.

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B.

Int J Gynecol Cancer. 2014 Jul 16. [Epub ahead of print]

PMID:
25033257
[PubMed - as supplied by publisher]
3.

Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study.

Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O, Trillsch F, Mahner S, Strauss HG, Wimberger P, Reuss A, du Bois A.

Support Care Cancer. 2014 Jul 5. [Epub ahead of print]

PMID:
24996831
[PubMed - as supplied by publisher]
4.

GCIG Consensus Review for Vulvovaginal Melanomas.

Leitao MM Jr, Cheng X, Hamilton AL, Siddiqui NA, Jurgenliemk-Schulz I, Mahner S, Lundqvist EA, Kim K, Freyer G.

Int J Gynecol Cancer. 2014 Jul 1. [Epub ahead of print]

PMID:
24987924
[PubMed - as supplied by publisher]
5.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.

PMID:
24889916
[PubMed - in process]
6.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C.

Geburtshilfe Frauenheilkd. 2013 Sep;73(9):874-889. No abstract available.

PMID:
24771937
[PubMed]
Free PMC Article
7.

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, Sehouli J, du Bois A, Wagner U; for the Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie.

Geburtshilfe Frauenheilkd. 2013 Mar;73(3):221-223.

PMID:
24771913
[PubMed]
Free PMC Article
8.

Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.

Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D.

Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67.

PMID:
24655477
[PubMed - in process]
Free PMC Article
9.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A.

Ann Oncol. 2014 Jul;25(7):1320-7. doi: 10.1093/annonc/mdu119. Epub 2014 Mar 11.

PMID:
24618151
[PubMed - in process]
10.

Quality of life as a primary endpoint in ovarian cancer trials.

Mahner S, Burges A.

Lancet Oncol. 2014 Apr;15(4):363-4. doi: 10.1016/S1470-2045(14)70084-1. Epub 2014 Feb 28. No abstract available.

PMID:
24582485
[PubMed - indexed for MEDLINE]
11.

Clinical management of epithelial ovarian cancer during pregnancy.

Grimm D, Woelber L, Trillsch F, Keller-v Amsberg G, Mahner S.

Eur J Cancer. 2014 Mar;50(5):963-71. doi: 10.1016/j.ejca.2013.12.020. Epub 2014 Jan 23. Review.

PMID:
24462638
[PubMed - indexed for MEDLINE]
12.

c-FOS suppresses ovarian cancer progression by changing adhesion.

Oliveira-Ferrer L, Rößler K, Haustein V, Schröder C, Wicklein D, Maltseva D, Khaustova N, Samatov T, Tonevitsky A, Mahner S, Jänicke F, Schumacher U, Milde-Langosch K.

Br J Cancer. 2014 Feb 4;110(3):753-63. doi: 10.1038/bjc.2013.774. Epub 2013 Dec 5.

PMID:
24322891
[PubMed - indexed for MEDLINE]
13.

Surgical intervention in relapsed ovarian cancer is beneficial: pro.

Harter P, Heitz F, Mahner S, Hilpert F, du Bois A.

Ann Oncol. 2013 Dec;24 Suppl 10:x33-34. doi: 10.1093/annonc/mdt466. Review.

PMID:
24265400
[PubMed - indexed for MEDLINE]
14.

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.

Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011. Epub 2013 Oct 28.

PMID:
24176298
[PubMed - indexed for MEDLINE]
15.

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.

Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss OJ, Meissner M, Hasan MT, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S.

Epigenetics. 2013 Nov;8(11):1226-35. doi: 10.4161/epi.26334. Epub 2013 Sep 26.

PMID:
24071829
[PubMed - in process]
Free Article
16.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.

Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.

BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.

PMID:
24044611
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The prognostic significance of Jun transcription factors in ovarian cancer.

Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Jänicke F, Milde-Langosch K.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1673-80. doi: 10.1007/s00432-013-1489-y. Epub 2013 Aug 13.

PMID:
23942796
[PubMed - indexed for MEDLINE]
18.

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.

Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20.

PMID:
23877013
[PubMed - indexed for MEDLINE]
19.

Adjuvant therapy in node-positive vulvar cancer.

Mahner S, Trillsch F, Kock L, Rohsbach D, Petersen C, Kruell A, Harter P, Jaenicke F, Woelber L.

Expert Rev Anticancer Ther. 2013 Jul;13(7):839-44. doi: 10.1586/14737140.2013.811063. Review.

PMID:
23875662
[PubMed - indexed for MEDLINE]
20.

Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.

Mathey S, Graeser MK, Zu Eulenburg C, Woelber L, Trillsch F, Jaenicke F, Müller V, Milde-Langosch K, Mahner S.

Oncology. 2013;85(2):69-77. doi: 10.1159/000351032. Epub 2013 Jul 16.

PMID:
23860180
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk